Why is Regencell Bioscience facing a securities class action lawsuit?

Investors allege Regencell made misleading statements about risks tied to market manipulation and extreme volatility in its stock.

What are investors claiming about Regencell’s stock volatility?

The complaint alleges the company failed to disclose that its shares were highly vulnerable to abnormal price swings and manipulation.

Why is market manipulation mentioned in the Regencell lawsuit?

Investors claim the company was exposed to trading activity that artificially influenced its stock price.

How could stock volatility affect Regencell investors?

Sharp and unpredictable price swings can lead to sudden losses and increased investment risk.

What are investors alleging Regencell failed to disclose?

Plaintiffs claim the company did not fully disclose the extent of manipulation risks and their potential impact.

Why are regulatory risks important in the Regencell case?

Exposure to manipulation may trigger investigations or enforcement actions that affect operations and reputation.

How can market manipulation impact a company’s stock price?

Artificial trading activity can inflate prices temporarily before a correction leads to declines.

What reputational risks are mentioned in the Regencell lawsuit?

The complaint alleges that volatility and manipulation concerns could harm investor trust and company credibility.

Who may qualify to participate in the Regencell class action?

Investors who purchased Regencell securities between October 28, 2024 and October 31, 2025 may be eligible if they suffered losses.

What is the deadline to seek lead plaintiff status in the Regencell lawsuit?

Investors seeking appointment as lead plaintiff must file a motion by June 23, 2026.

What is a securities class action lawsuit?

A securities class action allows investors to collectively pursue claims against a company for misleading statements or omissions.

What does the term “class period” mean in a securities lawsuit?

The class period is the timeframe when alleged misleading statements occurred and investors may have purchased the stock.

What is a lead plaintiff in a securities class action?

The lead plaintiff is the investor selected by the court to represent the interests of all shareholders in the case.

Do investors need to pay legal fees to join a securities class action?

Most securities cases are handled on contingency, meaning attorneys are paid only if there is a recovery.

How do investors receive compensation from a securities class action settlement?

If a settlement is reached, investors submit claim forms documenting their trades to receive a portion of the settlement fund.

Regencell Bioscience Holdings Limited

Join Action

Case Details

Ticker RGC

Class Period 10/28/2024 - 10/31/2025

Lead Plaintiff Deadline 06/23/2026

Days Left to Seek Plaintiff

If you are an Regencell Bioscience investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regencell To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Regencell between October 28, 2024 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regencell Bioscience Holdings Limited. (“Regencell” or the “Company”) (NASDAQ: RGC) and reminds investors of the June 23, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Regencell was vulnerable and/or subject to market manipulation; (ii) the resulting volatility in the market for the Company’s ordinary shares exposed Regencell’s investors to significant financial risk; (iii) all the foregoing subjected Regencell to a heightened risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant legal, monetary, and reputational harm; and (iv) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Lead Plaintiff Deadline: June 23, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action

Regencell Bioscience Holdings Limited

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify